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Abstract
Background: Uveitis describes a group of inflammatory conditions affecting the eye. The ability to monitor
inflammatory changes in anterior uveitis is crucial in clinical practice for making treatment decisions and in
clinical trials for testing therapeutic agents. The current standard for quantifying anterior segment inflammation is
clinical slit-lamp examination findings classified using the Standardisation of Uveitis Nomenclature (SUN) grading
system. Such clinical grading systems rely on a subjective estimation using the slit lamp and are often non-linear and
non-continuous scales, with large increases in cell count between each grade. Novel instrument-based technologies
have emerged over the last few decades, which can provide objective and quantifiable measurements. This review will
evaluate the reliability of such technologies and their level of agreement with anterior chamber (AC) cell count using
clinical slit-lamp examination.
Methods: Standard systematic review methodology will be used to identify, select and extract data from studies that
report the use of any instrument-based technology in the assessment of AC cells. Searches will be conducted through
bibliographic databases (MEDLINE, EMBASE and Cochrane Library), clinical trial registries and the grey literature. No
restrictions will be placed on language or year of publication. The outcomes of interest are the correlation of index test
measurements of AC cells with clinical grading systems using slit-lamp examination and the reliability of each index
test identified. Quality assessment will be undertaken using QUADAS2. Degree of correlation between the index and
reference test measures will be pooled and meta-analysed if appropriate.
Discussion: A number of instrument-based tools are available for measuring AC cells. This review will evaluate the
technologies available and measure the level of correlation of these alternative methods with clinical grading systems
as well as their performance in reliability and repeatability. The findings of this review will identify those objective,
instrument-based technologies which show good utility for measuring AC cells in a quantifiable way and which
warrant further exploration for their sensitivity and reliability over the current standard.
Systematic review registration: PROSPERO CRD42017084156 (Liu X, Moore DJ, Denniston AK). Instrument-based
tests for measuring anterior chamber (AC) cells in uveitis: a systematic review. 2017). Study screening stage is
complete. Data extraction stage has not yet commenced.
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Background
Uveitis is a group of inflammatory conditions affecting
the eye. It is a major cause of blindness globally, with an
estimated prevalence of 38 to 114.5 per 100,000 popula-
tion [1–3]. Uveitis can occur in any age, but it has a ten-
dency to affect the working-age group, thus having a
high socio-economic impact [1].
The Standardisation of Uveitis Nomenclature (SUN)
Working Group classifies uveitis based on the anatom-
ical focus of inflammation: anterior (anterior chamber),
intermediate (vitreous), posterior (retina and/or choroid)
and panuveitis (all anatomical parts) [4]. This systematic
review focuses on inflammation in the anterior chamber,
where inflammation causes a disruption to the normal
blood-aqueous barrier, resulting in leakage of cells into
the aqueous humour. These cells can be observed as
floating particles in the anterior chamber (AC). An in-
crease or decrease in the number of AC cells can be in-
dicative of improving or worsening disease and are
critical in identifying active inflammation and rationalis-
ing treatment decisions [4].
Clinical examination of AC cells
The current standard measurement as defined by the
SUN grading system is clinical examination by slit-lamp
biomicroscopy, whereby a clinician aims a 1 × 1-mm slit
beam through the anterior chamber and counts the
number of cells visible in the lit area [4]. The cell count
is placed into one of six grades in the SUN grading sys-
tem (Table 1). Prior to the SUN grading system, a num-
ber of alternative systems existed which attempt to
quantify cells in the same way; however, the SUN grad-
ing system is now the accepted standard for clinical
practice and for clinical trials [5–9].
Optical coherence tomography
In the last few decades, novel ophthalmic imaging tech-
niques such as optical coherence tomography (OCT)
have become widely adopted and provide new ways of
quantifying disease through instrument-based measure-
ments. OCT is fast, non-invasive and provides a
quantifiable measure of ocular structure that is more
sensitive and reliable than clinical estimates. Anterior
segment optical coherence tomography (AS-OCT) can
provide cross-sectional imaging of the AC and is able to
identify cells in the anterior chamber as hyper-reflective
dots. Several studies have suggested that AC cell count
on OCT correlates with clinical grading [10, 11]. Add-
itionally, the number of dots/cells in a given volume of
aqueous humour can be counted manually or with auto-
mated software [12].
Laser flare and cell photometry
The laser flare meter was introduced in 1988 for quanti-
fication of anterior chamber protein and cells [13]. It is a
fast and non-invasive technique which measures the
amount of light scatter from particles as a laser beam is
projected into the anterior chamber. The amount of
back-scattered light is proportional to the concentration
and size of proteins and cells in the aqueous humour.
Laser flare-cell photometry is primarily used in the es-
timation of AC flare (the hazy appearance given to the
aqueous fluid by inflammatory proteinaceous leakage);
however, certain models can be used for counting AC
cells. Counting of cells by laser photometry is reported
to be less accurate than its use in measuring flare, par-
ticularly in the extreme ends of the spectrum [14].
Purpose
Although we are aware of two main instrument-based
techniques for quantifying AC cells, it is possible that
more technologies, newer generations of the same tech-
nologies or the same technologies accompanied by
newer acquisition techniques and software automation
are available. The aim of this systematic review is to in-
vestigate all instrument-based methods for quantifying
AC cells and evaluate the correlation of these measures
with clinical grading using slit-lamp examination in pa-
tients with uveitis. Where reported, we will also compare
the level of reliability and repeatability for these methods
to determine which yields the most reliable results. For
the purposes of this review, we will refer to all
instrument-based methods as ‘index tests’.
Aim
To investigate which instrument-based technologies for
measuring anterior chamber cells in uveitis are available
and assess their level of validation.
The following questions are proposed:
 Which non-invasive instrument-based tests (index
tests) have the potential to measure anterior
chamber cells in uveitis?
 What is the level of agreement between each index
test and grading by clinical examination?
Table 1 The Standardisation of Uveitis Nomenclature (SUN)
working group grading scheme for anterior chamber cells
Grade Cells in field
0 < 1
0.5 + 1–5
1 + 6–15
2 + 16–25
3 + 26–50
4 + > 50
Standardisation of uveitis nomenclature for reporting clinical data. Results of
the First International Workshop. [4]
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 What is the reliability and repeatability of each
index test?
Methods
Protocol
This protocol is designed as per guidelines of Preferred
Reporting Items for Systematic Review and
Meta-Analysis Protocol (PRISMA-P) [15]. The system-
atic review will be reported in accordance to the
PRISMA guidelines [16].
Systematic review registration
Our protocol has been registered on PROSPERO
(CRD42017084156) [17].
Searches
Databases
The relevant data for this review is likely to come from
studies assessing a variety of quantitative research ques-
tions in uveitis; therefore, our search strategy will reflect
the pathological finding of interest ‘anterior chamber
cells’ and the disease context ‘uveitis’. No search terms
will be applied for the ‘technologies/tests’ to maximise
sensitivity of the search. For bibliographic databases,
free text and index terms (where available) will be
combined for each search element. A sample search
strategy for MEDLINE can be found in the Appendix.
We will search:
 Bibliographic databases of published studies
 MEDLINE (Ovid), 1946–present
 Embase (Ovid), 1947–present
 The Cochrane library, database inception–present
 Centre for Reviews and Dissemination database
(Health Technology Assessments and the Database
of Abstracts and Reviews of Effects), database
inception - present
 Registers of clinical trials
 Clinicaltrials.gov (www.clinicaltrials.gov)
 WHO International Clinical Trials Registry
Platform (ICTRP portal) (www.who.int/ictrp)
 Abstract and conference proceedings
 British library Ethos
 ProQuest (www.proquest.com)
 Dissertations and theses
 British Library’s ZETOC
 Conference Proceedings Citation Index (Web of
Science)
 Grey literature
 OpenGrey (www.opengrey.eu)
No restrictions will be placed on year or language of
publication. The literature search results will be entered
onto EndNote × 8.2 (Clarivate Analytics, Philadelphia,
PA) to facilitate removal of duplicates, study selection,
recording decisions and references. References to other
works will be considered for inclusion.
Selection criteria
Participants/population
The populations of interest are those with evidence of
anterior chamber cells and/or a diagnosis of uveitis, irre-
spective of active or inactive inflammation. There will be
no restrictions on age, gender, ethnicity, or underlying
aetiology or anatomical subtype. Studies with only
healthy participants and studies on animals will not be
included.
Index test
Included studies should describe one or more
instrument-based methods for counting the number of
anterior chamber (AC) cells.
Comparator
Included studies should use a clinical grading system
(such as the SUN grading system) as a comparator.
Primary outcome
The primary outcome is the correlation between index
tests and the clinical grading system; the reported out-
come should be a correlation coefficient for the two
measures. Studies which do not report a correlation co-
efficient but report matched measurements for the index
and reference tests can be included, and the correlation
coefficient extrapolated during analysis.
Additional outcome
To assess the reliability of a test, inclusion of a compara-
tor is not required. The outcome of interest is intra/in-
ter-observer reliability and repeatability of an index test
in the same population as above.
Type of study
There will be no restrictions on study design; however,
evaluation of correlation between index test and clinical
grading using slit-lamp examination requires both tests
to be done in a cross-sectional manner. Only those stud-
ies where measurements are taken within a reasonable
time point (within 24 h of each other) will be included.
Case reports involving only one subject, commentar-
ies, opinion articles and pictorial articles will not be
included.
Selection process
Titles and abstracts of records returned by the searches
will be screened for relevance to the review, to remove
obviously irrelevant studies Two independent reviewers
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will carry out quality assessment and reach consensus by
discussion or referral to a third reviewer.
Full text of potentially relevant articles will be re-
trieved and assessed for inclusion in the review against
the full selection criteria.
Data extraction
Data will be extracted from the included studies using a
standardised data extraction form in Microsoft Excel
(Microsoft, Washington, UK). The extraction process
will be carried out by two independent reviewers with
referral to a third reviewer if necessary. Information to
be extracted from all studies include the following:
 Study characteristics
 Title, authors, publication year, journal and
language
 Sample size
 Study design
 Index test used
1. Manufacturer and model (including
resolution and scan speed)
2. Image acquisition settings
3. Area, volume and position scanned in the AC
4. Software for image analysis and level of
automation (manual, semi-automated or
fully automated)
 Clinical grading system measurements
1. Observer (same observer or different observers)
2. Description of grading system used,
including the name of the system, number
of grades and number of cells in each grade
3. Slit lamp settings such as area and brightness
of illumination
 Patients’ characteristics
 Age, gender and ethnicity
 Underlying aetiologies (type of uveitis, anatomical
subtype, aetiological classification)
 Active or inactive disease
 If the study involves a therapeutic intervention:
treatment details (indication, drug, dosage, route,
subject pre/post-treatment status and length of
follow-up)
 Outcomes and findings
 Data will be extracted in preparation for two
separate analyses depending on the data reported:
1. Evaluation of correlation between index tests
and a clinical grading system: Studies which
include AC cell measurement by both index
test and a clinical grading system in the same
population will be used to evaluate the level
of correlation between the two tests. The
correlation coefficient reported will be
directly extracted. If no correlation coefficient
is reported, we will extract index and reference
test measurements, providing they are matched,
and calculate the correlation coefficient. If the
two measurements are not matched, we will
contact the authors for matched measurements.
2. Evaluation of reliability and repeatability of
an index test: Studies which report intra- and
inter-observer reliability for a study will be
analysed separately for assessment of
repeatability. The reported kappa values
will be extracted for intra-observer reliability
and inter-observer reliability.
 Cross-sectional measurements may be nested within
longitudinal studies whose primary aims are not to
compare performance or correlation between two
tests. In this situation, measurements at each time
point should be extracted and analysed as individual
cross-sectional comparisons
 Results of sub-analyses and sensitivity testing for
uveitis subtype (aetiological and anatomical) and
disease activity (active versus inactive disease)
Quality assessment
Quality assessment of all included studies will be based
on elements from the Quality Assessment of Diagnostic
Accuracy Studies tool (QUADAS2) [18]. Assessment will
be carried out at the study level. Two independent re-
viewers will carry out quality assessment and refer to a
third reviewer if needed.
It is anticipated that a small number of studies will meet
the inclusion criteria, with many of which being early
proof-of-concept studies with a high risk of bias. There-
fore, the risk of bias assessment and quality of evidence
will be reported but will not influence data synthesis.
For studies assessing the correlation between an index
and reference test, the following four risk of bias do-
mains will be rated as low, high or unclear [18]:
1. Selection of participants
a. Selection of participants with different degrees
of disease severity should be justified in the
context of assessing the full spectrum of disease,
as opposed to any prior knowledge of how
disease severity may affect test performance. As
severe inflammation (i.e. grade 4+) is less
prevalent than mild inflammation (i.e. + 0.5), a
random selection of participants would
invariably result in more participants with
milder disease than participants with severe
disease.
b. Exclusion of participants should be justified in
the context of interference with index test
measurement (i.e. corneal opacities may prevent
visualisation of AC structures behind it, or the
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presence of AC pigment may appear like AC
cells but is caused by a different pathological
process).
2. Index tests
a. We will consider whether index test acquisition
and analysis parameters were determined a
priori and consistent for all participants in the
study.
b. If analysis of index tests were done manually
(i.e. manual counting of AC cells in an image),
we will consider whether the observer was
blinded to the clinical AC cell grading, and vice
versa.
3. Reference test
a. We will consider whether assessment using the
clinical grading system in each study was
standardised, i.e. performed by the same
clinician, consistent slit-lamp settings such as
brightness of illumination and ambient settings
such as room lighting.
4. Flow and timing
a. Order of tests: The order of tests does not affect
the interpretability of results if the observer of
one test is blinded to the results of the other
test.
For studies assessing the reliability of a single index
test, the same assessment should be done for selection
of participants and index tests as above. Additional con-
siderations should be given for:
1. Intra-observer reliability studies: the conditions
under which index test repeatability was performed
should be reported and kept consistent (i.e. room
lighting, slit lamp beam intensity).
2. Inter-observer reliability studies: as well as the
points relating to intra-observer reliability, any
differences between observers (such as seniority and
experience) should be reported and accounted for.
Data synthesis
Data synthesis will be divided into analysis for the two
outcomes: correlation with reference test and reliability
of index test. For each outcome, a narrative synthesis of
tabulated evidence will be conducted and supported with
a meta-analysis where possible.
1. Evaluation of correlation between index and
reference test
a. These studies will be grouped by type of
technology (i.e. OCT, laser flare cell photometry).
For each type of technology, we are expecting
small numbers of studies; therefore, we will
analyse different platforms, generations or
manufacturers of the same technology together.
b. Studies will then be grouped by comparator (i.e.
different clinical grading systems).
c. If the data allows, correlation coefficients
between each index test versus reference test
will be compared and pooled for meta-analysis.
2. Evaluation of reliability and repeatability of an index
test
a. These studies will also be grouped by type of
technology, as described above.
b. Intra-observer and inter-observer reliability will
be analysed separately for each technology. If
the data allows, reliability measure (i.e. Kappa
values) will be compared and pooled for
meta-analysis.
Assessment of clinical and methodological homogen-
eity will determine whether studies are sufficiently
similar to allow for appropriate data pooling by
meta-analysis. Heterogeneity across studies in each
meta-analysis will be quantified using the I2 statistic. Ir-
respective of the ability to appropriately undertake any
meta-analyses, data will be reported narratively across all
studies for each grouping.
We will perform sensitivity analyses if there is signifi-
cant heterogeneity between studies. If data permits, we
will consider subgroup analyses for population groups
(i.e. age, gender and ethnicity), anatomical subtype of
uveitis and aetiological subtype. It is anticipated that
only a small number of studies will be relevant to the in-
clusion criteria, and this may limit our ability to carry
out meaningful subgroup analyses.
Discussion
The assessment of uveitis is complex: firstly, because
uveitis describes a heterogeneous group of diseases with
significant variations between different anatomical and
disease-specific subtypes, and secondly, because many
clinical measures in ophthalmology are based on visual
function (namely visual acuity), which are subjective to
the patient and do not always reflect active inflamma-
tion. Treatment for anterior uveitis, namely topical ste-
roids, carry side effects such as increased risk of
glaucoma and accelerated onset of cataract. The ability
to reliably measure ocular inflammation in uveitis is im-
portant for rationalising treatment in clinical practice
and assessing disease outcome in clinical trials.
Whilst the consensus Standardisation of Uveitis No-
menclature meeting of 2005 was a significant effort to-
wards defining a systematic method in assessing uveitic
inflammation, it is recognised that its reliance on clinical
examination remains subjective, unreliable and poorly
sensitive. A number of factors can affect the examiner’s
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ability to see AC cells including the slit lamp optics, the
degree of illumination, and the observer’s skills [19]. The
problem exists that clinical grading through examination
is error-prone and is therefore susceptible to
intra-observer and inter-observer variability [19, 20].
Clinical grading systems also typically classify levels of
severity into stepwise grades, in a non-continuous and
non-linear fashion, with a wider range of cell counts in
the higher grading groups (i.e. 26–50 cells in field for
grade 3+ and > 50 cells in field for 4+) than lower grad-
ing groups [4]. According to the SUN criteria, “improved
activity”, or a decrease in inflammation, requires a
two-step improvement or resolution to grade 0. How-
ever, a much larger reduction of AC cell count is re-
quired in higher grades of inflammation (i.e. 4+ to 2+
requires 50+ cells decreasing to 16–25 cells) than lower
grades (i.e. 2+ to 0.5+ requires 16–25 cells decreasing to
< 1 cells). This non-linear grading scale may not be able
to detect small changes, especially within higher grades
of inflammation, allowing potentially clinically meaning-
ful changes to go undetected. In clinical trials, this could
result in new therapies being deemed as failure, despite
having a clinically significant improvement.
Instrument-based technologies such as the laser
flare-cell photometer and OCT have shown potential for
assessing anterior chamber cells in several studies. These
instrument-based measures are less operator-dependent
and carry advantages such as objectivity. However, their
performance in these domains has not been compared in
a systematic way. The field of ophthalmic imaging is con-
tinuing to expand rapidly; therefore, it is timely to under-
take a systematic review to examine the evidence for
instrument-based measures of intraocular inflammation.
This systematic review will explore the range of tech-
nologies available for measuring AC cells to estimate
their level of reliability and correlation with clinical
grading systems. The findings from this review would
contribute to the process of validating instrument-based
methods for guiding treatment decisions in clinical care
and for measuring outcome in uveitis clinical trials.
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